News
Results from the Phase II WILLOW trial show that enpatoran achieved a statistically significant dose-response and clinically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback